Outcome of Board Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board approved the audited standalone and consolidated financial results for FY2026 ending 31 March 2026. Standalone revenue grew 62.6% to Rs. 8,154.97 lakh from Rs. 5,015.55 lakh, while consolidated revenue reached Rs. 8,203.23 lakh (up 60.9% YoY). Standalone PAT increased 30.5% to Rs. 327.10 lakh (FY2025: Rs. 250.71 lakh), with consolidated PAT at Rs. 448.16 lakh (up 78.1% YoY). The Board declared an un-modified (clean) audit opinion and recommended a final dividend of Rs. 0.25 per share (2.5% on Rs. 10 face value). The company also approved raising Rs. 13.09 crore via 11 lakh convertible warrants at Rs. 119 each to non-promoters, seeking to increase borrowing limits to Rs. 700 crore, acquiring a 10% stake in Virtuoso Infra Meditech LLP for Rs. 1.5 lakh, and appointing new internal and cost auditors.
Strong revenue growth of ~61% and PAT growth of ~78% (consolidated) are positive signals. However, the convertible warrants issuance will be dilutive to existing shareholders, and the proposed borrowing limit increase to Rs. 700 crore suggests higher debt levels ahead. The clean audit opinion removes audit-related concerns.